Previous close | 0.0500 |
Open | 0.0400 |
Bid | 0.0300 |
Ask | 0.0400 |
Strike | 80.00 |
Expiry date | 2024-01-19 |
Day's range | 0.0400 - 0.0400 |
Contract range | N/A |
Volume | |
Open interest | 1.71k |
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.